title: Comparison of high-sensitivity C-reactive protein and fetuin-A levels before and after treatment for subjects with subclinical hyperthyroidism.
abstract: This study was designed to show the effect of propylthiouracil treatment on sCD40L, high-sensitivity C-reactive protein, and fetuin-A levels on subjects with subclinical hyperthyroidism. After checking sCD40L, high-sensitivity C-reactive protein, and fetuin-A levels of 35 patients with subclinical hyperthyroidism, each was given 50 mg tablets of propylthiouracil three times daily. After 3 months, sCD40L, high-sensitivity C-reactive protein, and fetuin-A levels were then compared to the levels before treatment. Although high-sensitivity C-reactive protein and sCD40L levels were normal in the subclinical hyperthyroidism patients compared to the healthy controls, fetuin-A levels were statistically significantly higher (*p = 0.022). After treatment, fetuin-A levels of subclinical hyperthyroidism patients decreased statistically significantly compared to the levels before treatment (**p = 0.026). sCD40L and high-sensitivity C-reactive protein levels did not have a statistically significant difference compared to the control group and post-propylthiouracil treatment. In subclinical hyperthyroidism patients, high fetuin-A levels before propylthiouracil treatment and decreases in these levels after treatment in cases with subclinical hyperthyroidism indicated the possibility of preventing long-term cardiac complications with propylthiouracil treatment.
authors.affiliation: Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, 35380, Izmir, Turkey, oktaybilgir@gmail.com.
authors.forename: Oktay
authors.initials: O
authors.lastname: Bilgir
authors.forename: Ferda
authors.initials: F
authors.lastname: Bilgir
authors.forename: Tuba
authors.initials: T
authors.lastname: Topcuoglu
authors.forename: Mehmet
authors.initials: M
authors.lastname: Calan
authors.forename: Ozlem
authors.initials: O
authors.lastname: Calan
mesh_terms: D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism*; D023201:CD40 Ligand / Q000378:metabolism; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism*; D008297:Male; D011441:Propylthiouracil / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D060749:alpha-2-HS-Glycoprotein / Q000378:metabolism*
chemical_list: D013956:Antithyroid Agents; D015415:Biomarkers; D060749:alpha-2-HS-Glycoprotein; D023201:CD40 Ligand; D011441:Propylthiouracil; D002097:C-Reactive Protein